Research ArticlesMedicine

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

See allHide authors and affiliations

Science Translational Medicine  14 Jan 2015:
Vol. 7, Issue 270, pp. 270ra4
DOI: 10.1126/scitranslmed.3010298

Taking a Shot at HIV

HIV-1 transmission during vaginal intercourse remains a major public health issue. Antiretrovirals can prevent HIV-1 transmission when used as preexposure prophylaxis, but results are highly dependent on patient adherence to prescribed therapy. One possible solution to this limitation is the use of long-acting injectable agents. Andrews et al. used an animal model that simulates the heterosexual transmission of HIV-1 to women and found that GSK744 LA, a long-acting integrase inhibitor amenable to dosing every 3 months in humans, is highly protective against viral transmission. These results support further clinical trials in women at risk for HIV-1 infection.